Evidence map›Paper›PMID 42531138›Full record

ArticleAngewandte Chemie (International ed. in English)2026

In Silico to In Cerebro-Development of the Orexin Receptor Antagonist "Photorexant" for Photomodulation In Vitro and in Mouse Brains.

Marcus Angermann, Marie H Deventer, Vicente Ledesma-Martin, Nuno Martinho, Alix Flake, Silvia Mori, Angel Nuñez, Jaime Pignatelli, Rita C Guedes, Christophe P Stove and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marcus AngermannPharmazeutische und Medizinische Chemie, Institut für Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universität (JMU) Würzburg, Würzburg, Germany.
Marie H DeventerFaculty of Pharmaceutical Sciences, Department of Bioanalysis, Laboratory of Toxicology, Ghent University, Ghent, Belgium.
Vicente Ledesma-MartinPharmazeutische und Medizinische Chemie, Institut für Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universität (JMU) Würzburg, Würzburg, Germany.
Nuno MartinhoResearch Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal.
Alix FlakePharmazeutische und Medizinische Chemie, Institut für Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universität (JMU) Würzburg, Würzburg, Germany.
Silvia MoriPharmazeutische und Medizinische Chemie, Institut für Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universität (JMU) Würzburg, Würzburg, Germany.
Angel NuñezDepartment of Anatomy, Histology and Neurosciences, Universidad Autónoma de Madrid, Madrid, Spain.
Jaime PignatelliDepartment of Translational Neuroscience, Cajal Research Center for Neuroscience, Consejo Superior de Investigaciones Cientificas, Alcalá de Henares, Spain.
Rita C GuedesResearch Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal.
Christophe P StoveFaculty of Pharmaceutical Sciences, Department of Bioanalysis, Laboratory of Toxicology, Ghent University, Ghent, Belgium.ORCID https://orcid.org/0000-0001-7126-348X
Michael DeckerPharmazeutische und Medizinische Chemie, Institut für Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universität (JMU) Würzburg, Würzburg, Germany.ORCID https://orcid.org/0000-0002-6773-6245

Funding

Alzheimer Forschung Initiative R2602Deutsche Forschunsggemeinschaft (DFG) 559839626Deutsche Forschunsggemeinschaft (DFG) DFGDE1546/12-1Deutscher Akademischer Austauschdienst 57764664Fundação para a Ciência e a Tecnologia (FCT) 2023.18347.ICDTFundação para a Ciência e a Tecnologia (FCT) 2024.07837.CBMFundação para a Ciência e a Tecnologia (FCT) UID/04138/2025Marie Skłodowska-Curie Actions 101072895(TClock4AD)Ministerio de Ciencia e Innovación CIBERNED(InstitutodeSaludCarlosIII,Spain)and2024AEP082,partoftheprojectPID2019-104376RB-I00fundedbyMCIN/AEI/10.13039/501100011033Ministerio de Ciencia e Innovación PID2024-158246OB-I00Research Foundation Flanders (FWO) 1S54521NStudienstiftung des deutschen Volkes) and Marianne-Plehn Program
6 · The paper itself

Abstract

In this study, we report the first photoswitchable small molecule dual ligands for the orexin receptor subtypes 1 (OX1R) and 2 (OX2R) as molecular tools for optical control of orexin signaling. The orexin system is critical for several physiological processes and has been increasingly implicated in the pathogenesis of various psychiatric disorders. We implemented a prospective structure-based design approach, generating azobenzene-containing derivatives of the FDA-approved dual orexin receptor antagonist suvorexant with a computational workflow that featured a novel fragmentation and azobenzene-fusion strategy. The derivatives were subsequently evaluated by molecular docking to ensure preservation of the characteristic binding mode of suvorexant. Top candidates were synthesized and characterized by photophysical and pharmacological methods, namely our recently developed β-arrestin 2 and miniGα

Indexed as

AzepinesBrainOrexin Receptor AntagonistsOrexin ReceptorsTriazolesAnimalsHumansMiceMolecular Docking SimulationAzepinesOrexin Receptor AntagonistsOrexin ReceptorssuvorexantTriazolesantagonistcomputational chemistryGPCRneuromodulationphotopharmacology

Identifiers

PMID42531138
PMCPMC13653633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.